| 查看: 1375 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
药学专硕调剂
已经有0人回复
-
publcif的使用
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有152人回复
-
求调剂
已经有2人回复
-
会计专硕求调剂
已经有0人回复
-
新加坡国立大学药学系化学生物学课题组招PhD
已经有14人回复
-
请教酰胺缩合反应
已经有4人回复
-
一志愿大连理工制药工程专硕086002，本科211，总分342
已经有0人回复
-
制药工程专业招收调剂，要求过国家线
已经有0人回复
-
五邑大学药物化学生物学团队-李兰清课题组招收调剂学生
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
山东建筑大学材料类研究生招生调剂
+3/197
-
Postdoc position in Hangzhou Normal University （陈健翔组博后招聘）
+1/83
-
重庆交通大学院士团队招收材料、能源动力专业硕士研究生
+2/50
-
招聘︱国家纳米科学中心丁宝全杰青团队诚聘博士后（特别研究助理）
+2/48
-
广东唯一石化院校——资源与环境专硕招生
+1/42
-
赣南师范大学智能制造与未来能源学院2026年硕士调剂信息
+1/41
-
2026 年山东建筑大学金属增材制造方向硕士研究生调剂公告
+1/39
-
天津城建大学招收物理、化学或者生物调剂生一名，前往天津大学联合培养
+1/38
-
招聘︱国家纳米科学中心丁宝全杰青团队诚聘博士后（特别研究助理）
+2/34
-
【211博士招生】环境化学、地学、毒理方向，擅长污染物迁移转化降解、计算模拟者优先
+1/33
-
福建师范大学环境与资源学院环境电化学课题组招收2026硕士（含调剂）
+1/29
-
API项目寻求落地合作
+1/23
-
上海中医药大学创新中药研究院 招收审核制博士生一名
+1/17
-
【实战型】【生物医药】2026青岛大学招博士生 含少数民族骨干计划2名！
+1/14
-
广东唯一石化院校——资源与环境专硕招生
+1/12
-
烟台大学精准材料高等研究院26年材料方向研究生招生
+1/12
-
【2026调剂】南方科技大学-深圳理工大学-中科院 联培086000免疫方向(26.9入学)
+1/11
-
计算机(11408)考研361分求调剂
+1/4
-
基于机器学习和人工智能的结构/合金设计-西安交大
+1/4
-
招收从事大气复合污染成因领域研究生
+1/3
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
10楼2015-09-01 08:19:15
11楼2015-09-14 11:50:36
